Concepedia

Publication | Open Access

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

DOIFull Paper Access

707

Citations

30

References

2018

Year

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, Tim Illidge, Michelle A. Fanale, Ranjana H. Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo‐Doménech,
The Lancet

Abstract

Seattle Genetics Inc, Millennium Pharmaceuticals Inc, a wholly owned subsidiary of Takeda Pharmacuetical Company Limited, and National Institutes of Health National Cancer Institute Cancer Center.

References

YearCitations

Page 1